Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics

IF 15.2 1区医学 Q1 PHARMACOLOGY & PHARMACY Advanced drug delivery reviews Pub Date : 2024-04-03 DOI:10.1016/j.addr.2024.115302

Paula Gil-Cabrerizo , Teresa Simon-Yarza , Elisa Garbayo , María J. Blanco Prieto

{"title":"Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics","authors":"Paula Gil-Cabrerizo , Teresa Simon-Yarza , Elisa Garbayo , María J. Blanco Prieto","doi":"10.1016/j.addr.2024.115302","DOIUrl":null,"url":null,"abstract":"<div><p>Cardiovascular diseases (CVDs) stand as the leading cause of death worldwide, posing a significant global health challenge. Consequently, the development of innovative therapeutic strategies to enhance CVDs treatment is imperative. RNA-based therapies, encompassing non-coding RNAs, mRNA, aptamers, and CRISPR/Cas9 technology, have emerged as promising tools for addressing CVDs. However, inherent challenges associated with RNA, such as poor cellular uptake, susceptibility to RNase degradation, and capture by the reticuloendothelial system, underscore the necessity of combining these therapies with effective drug delivery systems.</p><p>Various non-viral delivery systems, including extracellular vesicles, lipid-based carriers, polymeric and inorganic nanoparticles, as well as hydrogels, have shown promise in enhancing the efficacy of RNA therapeutics. In this review, we offer an overview of the most relevant RNA-based therapeutic strategies explored for addressing CVDs and emphasize the pivotal role of delivery systems in augmenting their effectiveness. Additionally, we discuss the current status of these therapies and the challenges that hinder their clinical translation.</p></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":null,"pages":null},"PeriodicalIF":15.2000,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169409X24001248/pdfft?md5=b7d72182b1c54ed96276ba384add1421&pid=1-s2.0-S0169409X24001248-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced drug delivery reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169409X24001248","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Cardiovascular diseases (CVDs) stand as the leading cause of death worldwide, posing a significant global health challenge. Consequently, the development of innovative therapeutic strategies to enhance CVDs treatment is imperative. RNA-based therapies, encompassing non-coding RNAs, mRNA, aptamers, and CRISPR/Cas9 technology, have emerged as promising tools for addressing CVDs. However, inherent challenges associated with RNA, such as poor cellular uptake, susceptibility to RNase degradation, and capture by the reticuloendothelial system, underscore the necessity of combining these therapies with effective drug delivery systems.

Various non-viral delivery systems, including extracellular vesicles, lipid-based carriers, polymeric and inorganic nanoparticles, as well as hydrogels, have shown promise in enhancing the efficacy of RNA therapeutics. In this review, we offer an overview of the most relevant RNA-based therapeutic strategies explored for addressing CVDs and emphasize the pivotal role of delivery systems in augmenting their effectiveness. Additionally, we discuss the current status of these therapies and the challenges that hinder their clinical translation.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

驾驭心血管疾病疗法中的 RNA 输送系统

心血管疾病（CVDs）是导致全球死亡的主要原因，对全球健康构成重大挑战。因此，开发创新的治疗策略以提高心血管疾病的治疗效果势在必行。基于 RNA 的疗法，包括非编码 RNA、mRNA、aptamers 和 CRISPR/Cas9 技术，已成为治疗心血管疾病的有前途的工具。然而，与 RNA 相关的固有挑战，如细胞摄取不良、易被 RNase 降解、被网状内皮系统捕获等，凸显了将这些疗法与有效的药物递送系统相结合的必要性。各种非病毒递送系统，包括细胞外囊泡、脂质载体、聚合物和无机纳米颗粒以及水凝胶，都显示出提高 RNA 疗法疗效的前景。在这篇综述中，我们概述了为治疗心血管疾病而探索的最相关的 RNA 治疗策略，并强调了递送系统在增强疗效方面的关键作用。此外，我们还讨论了这些疗法的现状以及阻碍其临床转化的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Advanced drug delivery reviews 医学-药学

CiteScore

28.10

自引率

5.00%

发文量

294

审稿时长

15.1 weeks

期刊介绍： The aim of the Journal is to provide a forum for the critical analysis of advanced drug and gene delivery systems and their applications in human and veterinary medicine. The Journal has a broad scope, covering the key issues for effective drug and gene delivery, from administration to site-specific delivery. In general, the Journal publishes review articles in a Theme Issue format. Each Theme Issue provides a comprehensive and critical examination of current and emerging research on the design and development of advanced drug and gene delivery systems and their application to experimental and clinical therapeutics. The goal is to illustrate the pivotal role of a multidisciplinary approach to modern drug delivery, encompassing the application of sound biological and physicochemical principles to the engineering of drug delivery systems to meet the therapeutic need at hand. Importantly the Editorial Team of ADDR asks that the authors effectively window the extensive volume of literature, pick the important contributions and explain their importance, produce a forward looking identification of the challenges facing the field and produce a Conclusions section with expert recommendations to address the issues.